Huvitz Co (065510) Fair Value & Analysis
Healthcare · KR · Market cap 71.1B KRW
Fair value as of: Jul 22, 2026
From 13 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 6,887 KRW to 6,908 KRW (+0.3%) since Jul 6, 2026. Share price −2.5% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- The models converge in a tight band (6,832 KRW to 7,783 KRW), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 6,410 KRW – 23,601 KRW · fair‑value band 6,832 KRW – 7,783 KRW · the 7,050 KRW price screens above the 6,908 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Huvitz Co (065510) currently trades at 7,050 KRW, while our model-based Fair Value estimate is 6,908 KRW, implying the stock looks roughly 2.0% fairly valued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Huvitz Co generated revenue of 118B KRW at a net margin of -3.2%. Revenue declined 0.7% year over year. It earns a return on equity of -3.2%. Net debt stands at 66.8B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 6,832 KRW (bear case) to 7,783 KRW (bull case); at 7,050 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -2%, 065510 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Multiples (9,840 KRW) versus Earnings-Based (6,156 KRW). Highest evidence: Growth DCF (80).
Notify me when 065510 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Huvitz Co., Ltd. develops and sells optometric medical equipment worldwide. The company offers ophthalmic and optical equipment comprising refractive equipment, such as auto ref-keratometers, auto lensmeters, digital refractors, chart projectors, and unit tables; and diagnostic equipment comprising slit lamps, non-contact tonometers, and applanation …
Full company description
Huvitz Co., Ltd. develops and sells optometric medical equipment worldwide. The company offers ophthalmic and optical equipment comprising refractive equipment, such as auto ref-keratometers, auto lensmeters, digital refractors, chart projectors, and unit tables; and diagnostic equipment comprising slit lamps, non-contact tonometers, and applanation tonometers, as well as ophthalmologic diagnostic and surgical systems. It also provides edging solutions, such as edgers, frame readers, auto-blockers with frame readers, blockers, drilling machines, and network solutions; and visual acuity testers and microscope systems. The company was formerly known as Mirae Optics Co., Ltd. and changed its name to Huvitz Co., Ltd. in 2002. Huvitz Co., Ltd. was founded in 1998 and is based in Anyang-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Huvitz Co reported revenue of 118B KRW in FY2025 versus 95.0B KRW in FY2021, a compound +5.6%/yr. Reported net income was −5.0B KRW in FY2025.
Watch 065510: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare Huvitz Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Huvitz Co (065510) overvalued or undervalued?
What is the fair value of 065510?
What is the quality score of 065510?
What is the revenue of Huvitz Co (065510)?
What is the net profit margin of 065510?
Does Huvitz Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Huvitz Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.